SUBSCribe
logo
twitterlinkedininstagramUser Profile
  • BIG STORY
  • PERSPECTIVE
    • Editor's Note
  • ENTERPRISE
    • STRATEGY
      • HIGH FIVE
      • AD Break
    • MARKETS
      • PIXTORY
        • SPECIALS
        • VIDEOS
        • WOMEN
        • C’est La Vie
          • My Favourite
          • Pursuit of Happiness
          • The Good Life
          • Hardbound
        • MAGAZINE
        • EVENTS
          • LEADING EDGE
          • SMART ENTERPRISE
        • Jingoism buried, IPO done, stock price up 50%. What next for Gland Pharma?

          Its IPO was talk of the town, but investors gave it a miss. Now, the company is having the last laugh

          V Keshavdev - December 10, 2020
        • New growth model

          Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?

          Kripa Mahalingam - July 26, 2019
        • Tricky Transition

          Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs

          N Mahalakshmi - July 16, 2019
        • The Eclipse of A Star

          Investors worry about poor corporate governance practices at Sun Pharma and price erosion in the US generics market

          Prathamesh Mulye - March 25, 2019
        • Cherry-Picking Fallen Angels — Part 2

          Here is a list of stocks that have fallen in the small and mid-cap carnage despite reporting robust numbers

          Prathamesh Mulye - July 19, 2018
        • The Comeback Plan

          Lupin is betting on its specialty drugs business to counter the pricing pressures in the US generics market 

          Khushboo Balani - October 03, 2017
        • Master Innovator

          Vishnukant Bhutada’s big bet on oncology has catapulted Shilpa Medicare into the global generics space

          Shilpa Elizabeth Abraham - June 09, 2017
        • Vivek Pandey

          Private portfolio manager Vivek Pandey is backing Wockhardt thanks to its long ANDA pipeline

          Vivek Pandey - December 10, 2015

        Latest Edition

        magcover
        March 12, 2021
        magcover
        February 26, 2021
        magcover
        February 12, 2021
        magcover
        January 29, 2021
        twitterlinkedininstagramUser Profile
        • BIG STORY
        • PERSPECTIVE
        • ENTERPRISE
        • STRATEGY
        • MARKETS
        • PIXTORY
        • SPECIALS
        • VIDEOS
        • WOMEN
        • C'EST LA VIE
        • MAGAZINE
        About us Contact usPrivacy PolicyTerms and ConditionsSitemap
        Copyright © 2019 Outlook Business!. All pages of the Website are subject to our terms and conditions and privacy policy. You must not reproduce, duplicate, copy, sell, resell or exploit any material on the Website for any commercial purposes.